<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1494" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1494/" /><meta name="ncbi_pagename" content="Vascular Ehlers-Danlos Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Vascular Ehlers-Danlos Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Vascular Ehlers-Danlos Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/02/21" /><meta name="citation_author" content="Peter H Byers" /><meta name="citation_pmid" content="20301667" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1494/" /><meta name="citation_keywords" content="EDS Type IV" /><meta name="citation_keywords" content="Ehlers-Danlos Syndrome, Vascular Type" /><meta name="citation_keywords" content="vEDS" /><meta name="citation_keywords" content="Ehlers-Danlos Syndrome, Vascular Type" /><meta name="citation_keywords" content="EDS Type IV" /><meta name="citation_keywords" content="vEDS" /><meta name="citation_keywords" content="Collagen alpha-1(III) chain" /><meta name="citation_keywords" content="COL3A1" /><meta name="citation_keywords" content="Vascular Ehlers-Danlos Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Vascular Ehlers-Danlos Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Peter H Byers" /><meta name="DC.Date" content="2019/02/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1494/" /><meta name="description" content="Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features – distal joint hypermobility, easy bruising, thin skin, and clubfeet – are most often present in those children ascertained without a major complication." /><meta name="og:title" content="Vascular Ehlers-Danlos Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features – distal joint hypermobility, easy bruising, thin skin, and clubfeet – are most often present in those children ascertained without a major complication." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1494/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/eds4/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1494/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AD7C5E040D4E10000000001D500B1.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1494_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1494_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/porphyria-var/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/vlcad/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1494_"><span class="title" itemprop="name">Vascular Ehlers-Danlos Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: EDS Type IV; Ehlers-Danlos Syndrome, Vascular Type; vEDS</div><p class="contrib-group"><span itemprop="author">Peter H Byers</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1494_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1494_ai__"><div class="contrib half_rhythm"><span itemprop="author">Peter H Byers</span>, MD<div class="affiliation small">Departments of Pathology and Medicine<br />University of Washington<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.wu@sreybp" class="oemail">ude.wu@sreybp</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 2, 1999</span>; Last Update: <span itemprop="dateModified">February 21, 2019</span>.</p><p><em>Estimated reading time: 28 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="eds4.Summary" itemprop="description"><h2 id="_eds4_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features &#x02013; distal joint hypermobility, easy bruising, thin skin, and clubfeet &#x02013; are most often present in those children ascertained without a major complication.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of vEDS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>COL3A1</i>, or, when <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> does not identify a <i>COL3A1</i> pathogenic variant, on biochemical analysis of type III procollagen from cultured fibroblasts.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Affected individuals are instructed to seek immediate medical attention for sudden, unexplained pain. Treatment may include medical or surgical management for arterial complications, bowel rupture, or uterine rupture during pregnancy.</p><p><i>Surveillance:</i> May include periodic arterial screening by ultrasound examination, magnetic resonance angiogram, or computed tomography angiogram with and without venous contrast. Blood pressure monitoring on a regular basis is recommended to allow for early treatment if hypertension develops.</p><p><i>Agents/circumstances to avoid:</i> Trauma (collision sports, heavy lifting, and weight training with extreme lifting); arteriography should be discouraged and used only to identify life-threatening sources of bleeding prior to surgical intervention because of the risk of vascular injury; routine colonoscopy in the absence of concerning symptoms or a strong family history of colon cancer; elective surgery unless the benefit is expected to be substantial.</p><p><i>Evaluation of relatives at risk:</i> The genetic status of at-risk relatives should be clarified through <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or clinical evaluation if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown.</p><p><i>Pregnancy management:</i> Affected women have a 5% mortality risk with each pregnancy. The issue of management and recommendations is complicated by the recognition that many of the women who became pregnant, and their providers, learn of the diagnosis at the time of delivery and the onset of complications. When the mother&#x02019;s diagnosis is known, maternal risks should be discussed and she should be followed in a high-risk obstetric program.</p><p><i>Other:</i> Affected individuals should carry documentation of their genetic diagnosis, such as a MedicAlert<sup>&#x000ae;</sup>, emergency letter, or vEDS "passport."</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Vascular EDS is almost always inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner, but rare examples of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> inheritance have been reported. About 50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have inherited the <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an affected parent, and about 50% of affected individuals have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant. Each child of an affected individual has a 50% chance of inheriting the pathogenic variant and developing the disorder. Prenatal testing for pregnancies at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible in families in which the pathogenic variant in <i>COL3A1</i> has been identified.</p></div></div><div id="eds4.Diagnosis"><h2 id="_eds4_Diagnosis_">Diagnosis</h2><div id="eds4.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Vascular Ehlers-Danlos syndrome (vEDS) <b>should be suspected</b> in individuals with any <b>one</b> of the following major diagnostic criteria or several minor diagnostic criteria, particularly in those younger than age 40 years. Clinical diagnostic criteria established in 2017 [<a class="bk_pop" href="#eds4.REF.malfait.2017.8">Malfait et al 2017</a>] are useful to guide the approach to genetic testing.</p><p><b>Major diagnostic criteria</b></p><ul><li class="half_rhythm"><div>Arterial aneurysms, dissection, or rupture</div></li><li class="half_rhythm"><div>Intestinal rupture</div></li><li class="half_rhythm"><div>Uterine rupture during pregnancy</div></li><li class="half_rhythm"><div>Family history of vEDS</div></li></ul><p><b>Minor diagnostic criteria</b></p><ul><li class="half_rhythm"><div>Thin, translucent skin (especially noticeable on the chest/abdomen)</div></li><li class="half_rhythm"><div>Characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes)</div></li><li class="half_rhythm"><div>Acrogeria (an aged appearance to the extremities, particularly the hands)</div></li><li class="half_rhythm"><div>Carotid-cavernous sinus arteriovenous fistula</div></li><li class="half_rhythm"><div>Hypermobility of small joints</div></li><li class="half_rhythm"><div>Tendon/muscle rupture</div></li><li class="half_rhythm"><div>Early-onset varicose veins</div></li><li class="half_rhythm"><div>Pneumothorax/hemopneumothorax</div></li><li class="half_rhythm"><div>Easy bruising (spontaneous or with minimal trauma)</div></li><li class="half_rhythm"><div>Chronic joint subluxations/dislocations</div></li><li class="half_rhythm"><div>Congenital dislocation of the hips</div></li><li class="half_rhythm"><div>Talipes equinovarus (clubfoot)</div></li></ul></div><div id="eds4.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of vEDS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with either of the following:</p><ul><li class="half_rhythm"><div>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>COL3A1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1494/table/eds4.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figeds4Tmoleculargenetictestingusedin" rid-ob="figobeds4Tmoleculargenetictestingusedin">Table 1</a>)</div></li><li class="half_rhythm"><div>Abnormalities in synthesis and mobility of type III collagen chains on <a href="#eds4.Biochemical_ProteinBased_Analysis">biochemical analysis</a> of type III procollagen from cultured fibroblasts when vEDS is suspected but <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> does not identify a <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></div></li></ul><p>Note: (1) When the diagnosis is suspected on clinical grounds, molecular diagnostic testing of <i>COL3A1</i> is indicated. (2) The presence of clinical phenocopies and variable expression of the vEDS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> warrant the molecular diagnostic approach.</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of vEDS is broad, individuals with the distinctive major criteria findings described in <a href="#eds4.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#eds4.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited connective tissue disorders are more likely to be diagnosed using genomic testing (see <a href="#eds4.Option_2">Option 2</a>).</p><div id="eds4.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of vEDS, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>COL3A1</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>COL3A1</i> and other genes of interest (see <a href="#eds4.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1494/table/eds4.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figeds4Tmoleculargenetictestingusedin" rid-ob="figobeds4Tmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="eds4.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited connective tissue disorders, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>If <b><a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a></b> is not diagnostic, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="eds4.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Vascular Ehlers-Danlos Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1494/table/eds4.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__eds4.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL3A1</i></td><td headers="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;95%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_eds4.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="eds4.TF.1.1"><p class="no_margin">See <a href="/books/NBK1494/#eds4.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="eds4.TF.1.2"><p class="no_margin">See <a href="#eds4.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="eds4.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="eds4.TF.1.4"><p class="no_margin">Author, personal observation</p></div></dd><dt>5. </dt><dd><div id="eds4.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="eds4.TF.1.6"><p class="no_margin">The low frequency of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> deletions is consistent with the failure to detect a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in 155 specimens submitted for <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> [<a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al 2014</a>; Author, personal experience; Collagen Diagnostic Laboratory]. One 3.5-Mb <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion/">contiguous gene deletion</a> that includes <i>COL3A1</i> was identified by MLPA [<a class="bk_pop" href="#eds4.REF.meienberg.2010.1315">Meienberg et al 2010</a>].</p></div></dd></dl></div></div></div></div><div id="eds4.Biochemical_ProteinBased_Analysis"><h4>Biochemical (Protein-Based) Analysis</h4><p>Biochemical testing for vEDS requires cultured dermal fibroblasts. Proteins synthesized by these cells are biosynthetically labeled with radiolabeled proline and assessed by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The amount of type III procollagen synthesized, the quantity secreted into the medium, and the electrophoretic mobility of the constituent chains are assessed.</p><p>Analysis of type III procollagen synthesized by cultured cells can identify abnormalities in synthesis and mobility of type III collagen chains. Alterations in mobility may result from substitutions for glycines in the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> because they lead to slow folding and increased post-translational modification, or as the result of deletions or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> or <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> alterations. This testing is used now almost exclusively to characterize the outcome of splice site alterations identified by DNA <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></div></div></div><div id="eds4.Clinical_Characteristics"><h2 id="_eds4_Clinical_Characteristics_">Clinical Characteristics</h2><div id="eds4.Clinical_Description"><h3>Clinical Description</h3><p>The most comprehensive descriptions of clinical features and natural history derive from two types of studies: a cross-sectional and retrospective view obtained at the time of diagnostic testing [<a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al 2014</a>] and a nearly 15-year-long cohort study from one group in France [<a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>]. A retrospective review of the health history of more than 1,200 individuals with vascular Ehlers-Danlos syndrome (vEDS) delineated the natural history of the disorder [<a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al 2014</a>]. The majority of individuals were ascertained on the basis of a major complication (70%), at an average age of 30 years. Median survival in the population was 50 years with a younger median survival in males (by 5 years) as compared to females, partially due to a higher rate of lethal vascular events in males than females before age 20 years. A similar rate of complications was reported in the French cohort of 215 individuals with vEDS, but the gender difference in mean survival was not observed [<a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>].</p><div id="eds4.Children"><h4>Children</h4><p>The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history [<a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al 2014</a>]. (See <a href="#eds4.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> and <a href="#eds4.Genetic_Counseling">Genetic Counseling</a> for discussion of genetic testing of at-risk children to facilitate appropriate intervention in the occurrence of a major complication and implementation of risk-reducing behaviors.)</p><ul><li class="half_rhythm"><div>Approximately 15% of these individuals had experienced a major complication of vEDS by the time of testing.</div></li><li class="half_rhythm"><div>Of the 121 children tested in the absence of a positive family history, 65 presented with a major complication at an average age of 11 years.</div></li><li class="half_rhythm"><div>Four minor diagnostic features &#x02013; distal joint hypermobility, easy bruising, thin skin, and clubfeet &#x02013; were most often present in those ascertained without a major complication.</div></li><li class="half_rhythm"><div>At birth, clubfoot (unilateral or bilateral) was noted in 8% of children with vEDS.</div></li><li class="half_rhythm"><div>Hip dislocation, limb deficiency, and amniotic bands appeared in approximately 1% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants.</div></li><li class="half_rhythm"><div>Death that occurred in the first two decades of life almost always resulted from spontaneous artery rupture or dissection.</div><ul><li class="half_rhythm"><div>Artery rupture, 60% of which involved the aorta, was responsible for all deaths in young males.</div></li><li class="half_rhythm"><div>Death before age 20 years was seen in a 3:1 ratio of males:females. This difference was not noted in the French study because ascertainment was restricted to adults.</div></li></ul></li></ul></div><div id="eds4.Adults"><h4>Adults</h4><p>Vascular rupture or dissection and gastrointestinal perforation or organ rupture are the presenting signs in 70% of adults with a <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#eds4.REF.rana.2011.229">Rana et al 2011</a>]<i>.</i></p><ul><li class="half_rhythm"><div>These complications are dramatic and often unexpected, presenting as sudden death, stroke and its neurologic sequelae, acute abdomen, retroperitoneal bleeding, uterine rupture at delivery, and/or shock.</div></li><li class="half_rhythm"><div>The average age for the first major arterial or gastrointestinal complication was 31 years in this reported group.</div></li></ul><p><b>Cardiovascular.</b> Vascular complications include rupture, aneurysm, and/or dissection of major or minor arteries.</p><ul><li class="half_rhythm"><div>Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection, or may occur spontaneously.</div></li><li class="half_rhythm"><div>The sites of arterial rupture are the thorax and abdomen (66%), head and neck (17%), and extremities (17%).</div></li><li class="half_rhythm"><div>The clinical presentation depends on the location of the arterial event.</div><ul><li class="half_rhythm"><div>Unexplained acute pain warrants immediate medical attention.</div></li><li class="half_rhythm"><div>Chest pain or symptoms of "heart attack" were described in 80% of the 26 individuals with vEDS later identified to have experienced a coronary artery dissection.</div></li></ul></li><li class="half_rhythm"><div>Ruptures of the chordae tendinae or ventricle of the heart are rare cardiovascular complications.</div></li><li class="half_rhythm"><div>Venous varicosities also occur.</div></li></ul><p><b>Gastrointestinal.</b> Perforation of the gastrointestinal (GI) tract occurs in approximately 15% of individuals with identified <i>COL3A1</i> pathogenic variants, though seldom in individuals with <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants.</p><ul><li class="half_rhythm"><div>Most GI perforations occur in the sigmoid colon.</div></li><li class="half_rhythm"><div>Ruptures of the small bowel and stomach have been reported, though infrequently.</div></li><li class="half_rhythm"><div>Iatrogenic perforation during colonoscopy has also been reported [<a class="bk_pop" href="#eds4.REF.rana.2011.229">Rana et al 2011</a>].</div></li><li class="half_rhythm"><div>Bowel rupture is rarely lethal (3%) [<a class="bk_pop" href="#eds4.REF.pepin.2000.673">Pepin et al 2000</a>], with most deaths reported as a result of unexpected hemorrhage or artery rupture during surgical repair.</div></li></ul><p>Surgical intervention for bowel rupture is often necessary and usually lifesaving, although treatment with antibiotics and fluid support has been used successfully [Author, personal observation]. The successful surgical approach to perforation repair in vEDS includes partial colectomy, colostomy and creation of a Hartman pouch, and reversal after several months. Reports of primary repair are few.</p><p>Complications during and following surgery are related to tissue and vessel friability, which result in recurrent arterial or bowel tears, fistulae, poor wound healing, and suture dehiscence. Individuals who survive a first complication may experience recurrent rupture. The timing and site of repeat rupture cannot be predicted by the first event. Recurrent perforation may lead to colonic resection.</p><p><b>Pulmonary.</b> Spontaneous and/or recurrent pneumothoraces may be the first significant presenting feature of vEDS.</p><ul><li class="half_rhythm"><div>Hemothorax and hemopneumothorax have been reported, often in association with pulmonary blebs, cystic lesions, and hemorrhagic or fibrous nodules.</div></li><li class="half_rhythm"><div>Hemoptysis can be severe and recurrent, even life threatening [<a class="bk_pop" href="#eds4.REF.hatake.2013.23">Hatake et al 2013</a>].</div></li><li class="half_rhythm"><div>Pathologic evaluation may demonstrate acute hematoma, fibrous nodules, vascular disruption, intraluminal and interstitial hemosiderosis, and emphysematous changes [<a class="bk_pop" href="#eds4.REF.kawabata.2010.944">Kawabata et al 2010</a>].</div></li><li class="half_rhythm"><div>Successful lung transplantation was reported in one individual with severe pulmonary complications of vEDS [<a class="bk_pop" href="#eds4.REF.garc_a_s_ez.2014.1804">Garc&#x000ed;a S&#x000e1;ez et al 2014</a>].</div></li></ul><p><b>Ocular.</b> Keratoconus has been reported in vEDS [<a class="bk_pop" href="#eds4.REF.kuming.1977.403">Kuming &#x00026; Joffe 1977</a>].</p><p>Carotid cavernous sinus fistulas typically present with sudden-onset ocular symptoms including blurred vision, diplopia, ocular pain, proptosis, and chemosis and almost always requires rapid intervention to save vision. It affects about 10% of individuals with vEDS with a preponderance among females [<a class="bk_pop" href="#eds4.REF.adham.2018.100">Adham et al 2018</a>].</p><p><b>Dental</b> complications include periodontal disease and gingival recession. A study by <a class="bk_pop" href="#eds4.REF.ferr_.2012.e000705">Ferr&#x000e9; et al [2012]</a> characterized the gingival <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in vEDS as generalized thinness and translucency of the gingiva with increased fragility. Disorders of the temporomandibular joint and defects in dentin formation are also more common in individuals with vEDS.</p><p><b>Other</b> rare complications include rupture of the spleen or liver [<a class="bk_pop" href="#eds4.REF.pepin.2000.673">Pepin et al 2000</a>, <a class="bk_pop" href="#eds4.REF.ng.2005.320">Ng &#x00026; Muiesan 2005</a>]. Elastosis perforans serpiginosa is a rare but reported skin finding [<a class="bk_pop" href="#eds4.REF.ahmadi.2011.226">Ahmadi &#x00026; Choi 2011</a>, <a class="bk_pop" href="#eds4.REF.ferr_.2012.e000705">Ferr&#x000e9; et al 2012</a>].</p></div></div><div id="eds4.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>More than 600 unique <i>COL3A1</i> pathogenic variants have been aggregated into the <a href="https://eds.gene.le.ac.uk/home.php?select_db=COL3A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ehlers Danlos Syndrome Variant Database</a> with an additional 250 in <a href="/clinvar/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinVar</a>. Approximately 5% of <i>COL3A1</i> variants result in <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a>. Individuals with a <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variant have a 15-year delay in onset of complications, improved life expectancy (close to that of the US population), and significantly fewer obstetric and bowel complications than are seen with other types of <i>COL3A1</i> pathogenic variants [<a class="bk_pop" href="#eds4.REF.leistritz.2011.717">Leistritz et al 2011</a>, <a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al 2014</a>, <a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>].</p><p>Among the 1,200 individuals with vEDS described by <a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al [2014]</a>, survival depended in part on the nature of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Survival was longest for those with a <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variant and shortest for those with a splice donor site variant that resulted in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping or a substitution for a triple helical glycine residue (in the repeating Gly-Xaa-Yaa triplets) by a large residue. The location of the variant within the triple helix did not have a discernable effect on survival. Similar survival patterns were described in the French cohort of 126 individuals with <i>COL3A1</i> pathogenic variants [<a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>]. These differences in populations are difficult to use to counsel individuals because of significant intra- and <a class="def" href="/books/n/gene/glossary/def-item/interfamilial-variability/">interfamilial variability</a> in age of complication and survival for the same pathogenic variant.</p></div><div id="eds4.Penetrance"><h3>Penetrance</h3><p>In families identified on the basis of clinical complications, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the vEDS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> appears to be close to 100% in adults with a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-skipping alteration; the age at which the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> becomes penetrant may vary. <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants have significantly reduced penetrance manifested by the absence of minor diagnostic criteria in 51% of individuals with vEDS identified with a pathogenic null alteration [<a class="bk_pop" href="#eds4.REF.leistritz.2011.717">Leistritz et al 2011</a>].</p></div><div id="eds4.Nomenclature"><h3>Nomenclature</h3><p>The following terms for vEDS have been used:</p><ul><li class="half_rhythm"><div><b>Ehlers Danlos syndrome type IV</b> was introduced by Beighton in his 1979 summary of heterogeneity in Ehlers Danlos syndrome.</div></li><li class="half_rhythm"><div><b>Status dysvascularis</b> was introduced by Georg Sack in 1936; the term was never used extensively.</div></li><li class="half_rhythm"><div><b>Familial acrogeria,</b> introduced by Heinrich Gottron in 1940, probably included some individuals with vEDS.</div></li><li class="half_rhythm"><div><b>Sack-Barabas syndrome</b> or the <b>Sack-Barabas type of Ehlers-Danlos syndrome</b> was used after <a class="bk_pop" href="#eds4.REF.barabas.1967.612">Barabas [1967]</a> introduced the disorder to the English-language literature.</div></li></ul></div><div id="eds4.Prevalence"><h3>Prevalence</h3><p>There are no good estimates of the prevalence of vEDS in any population. About 1,500 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in the United States have been identified on the basis of biochemical and genetic testing and analysis of family pedigrees [Author, personal observation], leading to a minimum prevalence estimate of 1:200,000. The decreased frequency of certain classes of pathogenic variants suggests that the overall prevalence of individuals with pathogenic variants in <i>COL3A1</i> (see <a href="#eds4.Molecular_Genetics">Molecular Genetics</a>) could approach that of individuals with pathogenic variants in <i>COL1A1</i>, which is estimated at close to 1:50,000.</p><p>Because many families with vEDS are identified only after a severe complication or death, it is likely that individuals/families with pathogenic variants in <i>COL3A1</i> and a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> do not come to medical attention and thus go undetected. In addition, because of the perceived rarity of the disorder, it is seldom considered and nonvascular complications may not raise diagnostic suspicion of vEDS.</p></div></div><div id="eds4.Genetically_Related_Allelic_Disorde"><h2 id="_eds4_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><a href="/books/n/gene/eds3/"><b>Hypermobile Ehlers-Danlos syndrome</b></a>
<b>(EDS type III).</b> A single report of a family with clinical features of EDS type III and a <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> typically associated with vEDS (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000090.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000090.3</a>: c.2410G&#x0003e;A, p.Gly804Ser; Gly637Ser in the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>) [<a class="bk_pop" href="#eds4.REF.narcisi.1994.1617">Narcisi et al 1994</a>] led to the suspicion of a causative relationship between variants in <i>COL3A1</i> and EDS type III; however, neither biochemical studies of collagen synthesis nor <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> have identified a type III collagen defect in any other individuals with the clinical diagnosis of EDS type III. The same family is cited in a paper by <a class="bk_pop" href="#eds4.REF.pope.1996.163">Pope et al [1996]</a> with an indication that there were three generations with hypermobility and no vascular events.</p><p><b>Familial aortic aneurysm.</b> Type III collagen glycine substitutions and <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> pathogenic variants are periodically reported in individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> aortic aneurysm [<a class="bk_pop" href="#eds4.REF.van_de_luijtgaarden.2015.881">van de Luijtgaarden et al 2015</a>]. In such publications, the ability to assess whether the vEDS clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is present is quite limited. These rare reports notwithstanding, existence of a subset of individuals with a <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> giving rise to the phenotype of familial aortic aneurysm in the absence of other findings of vEDS seems unlikely [Author, personal observation].</p></div><div id="eds4.Differential_Diagnosis"><h2 id="_eds4_Differential_Diagnosis_">Differential Diagnosis</h2><p>Other forms of Ehlers-Danlos syndrome (EDS) should be considered in individuals with easy bruising, joint hypermobility, and/or chronic joint dislocation who have normal collagen III biochemical studies or molecular analysis of <i>COL3A1</i>.</p><div id="eds4.T.disorders_to_consider_in_the_diff" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of vEDS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1494/table/eds4.T.disorders_to_consider_in_the_diff/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__eds4.T.disorders_to_consider_in_the_diff_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential Diagnosis Disorder</th><th id="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/vEDS</th><th headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from vEDS</th></tr></thead><tbody><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/eds/">Classic EDS</a></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL5A1</i><br /><i>COL5A2</i>&#x000a0;<sup>1</sup></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically not associated w/blood vessel, bowel, or organ rupture</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Soft, doughy, stretchy skin</div></li><li class="half_rhythm"><div>Abnormal scars</div></li><li class="half_rhythm"><div>Significant large-joint hypermobility</div></li></ul>
</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ehlers-Danlos classic/vascular type</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>COL1A1</i></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pathogenic variants in <i>COL1A1</i> (all result in substitutions of arginine by cysteine in the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>) have been reported in individuals w/classic EDS &#x00026; aneurysm &#x00026; dissection of large vessels&#x000a0;<sup>1</sup></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Similar to classic EDS</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Kyphoscoliotic EDS<br />(see <a href="/books/n/gene/fkbp14-keds/"><i>FKBP14</i>-kED</a>S &#x00026; <a href="/books/n/gene/eds6/"><i>PLOD1</i>-kEDS</a>)</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLOD1</i><br /><i>FKBP14</i></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vascular rupture may be a feature</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Progressive scoliosis</div></li><li class="half_rhythm"><div>Hypotonia</div></li><li class="half_rhythm"><div>Fragility of the globe</div></li></ul>
</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EDS, periodontal form<br />(OMIM <a href="http://omim.org/entry/130080" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">130080</a>, <a href="https://omim.org/entry/617174" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617174</a>)</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>C1R</i><br /><i>C1S</i></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bruising &#x00026; skin staining, particularly shins</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Rare</div></li><li class="half_rhythm"><div>Features of classic EDS + early periodontal friability, recession, &#x00026; tooth loss</div></li></ul>
</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Isolated arterial aneurysm</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Single arterial aneurysm or dissection</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually NOT the result of a type III collagen defect</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/loeys-dietz/">Loeys-Dietz syndrome</a></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMAD2</i><br /><i>SMAD3</i><br /><i>TGFB2</i><br /><i>TGFB3</i><br /><i>TGFBR1</i><br /><i>TGFBR2</i></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Vascular findings (cerebral, thoracic, &#x00026; abdominal arterial aneurysms &#x00026;/or dissections)</div></li><li class="half_rhythm"><div>Aggressive arterial aneurysms &#x00026; high incidence of pregnancy-related complications</div></li><li class="half_rhythm"><div>Thin translucent skin &#x00026; easy bruising</div></li></ul>
</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Skeletal manifestations</div></li><li class="half_rhythm"><div>Craniofacial anomalies</div></li><li class="half_rhythm"><div>Predisposition to allergic disease</div></li></ul>
</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pkd-ad/">Polycystic kidney disease, autosomal dominant</a> (ADPKD)</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PKD1</i><br /><i>PKD2&#x000a0;<sup>3</sup></i></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vascular abnormalities: intracranial aneurysms, aortic root dilatation, &#x00026; thoracic aorta dissection; mitral valve prolapse</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Generally late onset</div></li><li class="half_rhythm"><div>Bilateral renal cysts &#x00026; cysts in other organs</div></li><li class="half_rhythm"><div>Abdominal wall hernias</div></li><li class="half_rhythm"><div>Renal manifestations: hypertension, renal pain, &#x00026; renal insufficiency</div></li></ul>
</td></tr><tr><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/marfan/">Marfan syndrome</a></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FBN1</i></td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider Marfan syndrome if presenting vascular complication is an aortic aneurysm or dissection.</td><td headers="hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_eds4.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>vEDS &#x00026; Marfan syndrome usually can be distinguished relatively easily on physical examination.</div></li><li class="half_rhythm"><div>Individuals w/Marfan syndrome typically have dolichostenomelia &#x00026; arachnodactyly, lens dislocation, &#x00026; dilatation or aneurysm of only the aorta.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; EDS = Ehlers-Danlos syndrome; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="eds4.TF.2.1"><p class="no_margin">A <i>COL1A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Arg134Cys was identified in two unrelated children with classic EDS [<a class="bk_pop" href="#eds4.REF.nuytinck.2000.1398">Nuytinck et al 2000</a>]. The same substitution was subsequently identified in three unrelated persons with aneurysms and rupture of medium-sized arteries in young adulthood. These individuals also had thin and hyperextensible skin, easy bruising, and abnormal wound healing [<a class="bk_pop" href="#eds4.REF.malfait.2007.387">Malfait et al 2007</a>; Malfait &#x00026; De Paepe, personal observation]. Pathogenic variants in <i>COL1A1</i>, however, are not a major cause of classic EDS [<a class="bk_pop" href="#eds4.REF.malfait.2005.28">Malfait et al 2005</a>]. See <a href="/books/n/gene/eds/">EDS, Classic Type</a>.</p></div></dd><dt>2. </dt><dd><div id="eds4.TF.2.2"><p class="no_margin">Familial forms of arterial aneurysm have been linked to at least 16 identified genes (see <a href="/books/n/gene/taa/">Heritable Thoracic Aortic Disease Overview</a>).</p></div></dd><dt>3. </dt><dd><div id="eds4.TF.2.3"><p class="no_margin">Pathogenic variants <i>GANAB</i> and <i>DNAJB11</i> may also be associated with ADPKD in rare cases (see <a href="/books/n/gene/pkd-ad/">ADPKD</a>).</p></div></dd></dl></div></div></div></div><div id="eds4.Management"><h2 id="_eds4_Management_">Management</h2><div id="eds4.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>There is currently no consensus regarding the appropriate extent of evaluation at the time of initial diagnosis. To establish the extent of disease and needs in an individual diagnosed with vEDS, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Because of the risk for asymptomatic aneurysm/dissection, initial visualization of the arterial tree is commonly undertaken [<a class="bk_pop" href="#eds4.REF.chu.2014.1120">Chu et al 2014</a>, <a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>]; the approach employed varies by geographic region and by institution (see <a href="#eds4.Surveillance">Surveillance</a>). Approach to a vascular evaluation depends on the age of the patient and the circumstances in which the diagnosis is made.</div></li><li class="half_rhythm"><div>Because no specific gastrointestinal findings are known to precede or predict bowel rupture, invasive GI evaluation is of no benefit.</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor is recommended.</div></li><li class="half_rhythm"><div>Following diagnosis, the most crucial aspect of management is the creation of an organized care team. See <a href="#eds4.Treatment_of_Manifestations">Treatment of Manifestations</a>.</div></li><li class="half_rhythm"><div>Review lifestyle with the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and emphasize the importance of minimizing collision activities and sports.</div></li></ul></div><div id="eds4.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The most crucial aspect of management is the creation of an organized care team that includes a primary care physician, vascular surgeon, and general surgeon; a geneticist may aid in integration of care. This team is responsible for the organization of ordinary and extraordinary care. In addition, individuals with vEDS should carry documentation of their genetic diagnosis, such as a MedicAlert<sup>&#x000ae;</sup>, emergency letter, or vEDS "passport."</p><p>Affected individuals should be instructed to seek immediate medical attention for sudden, unexplained pain.</p><p>Surgical intervention may be lifesaving in the face of bowel rupture, arterial rupture, or organ rupture (e.g., the uterus in pregnancy).</p><ul><li class="half_rhythm"><div>When surgery is required for treatment, it is appropriate to target the approach and minimize surgical exploration because of the risk of inadvertent damage to other tissues [<a class="bk_pop" href="#eds4.REF.oderich.2005.98">Oderich et al 2005</a>]. In addition, an approach of "judicious underhydration" may help to prevent the recognized cycle of complications.</div></li><li class="half_rhythm"><div>In general, surgical procedures are more likely to be successful when the treating physician is aware of the diagnosis of vEDS and its associated tissue fragility [<a class="bk_pop" href="#eds4.REF.shalhub.2014.160">Shalhub et al 2014</a>].</div></li></ul><p>There are no guidelines to direct recommendations for elective repair in individuals with aneurysm(s) and vEDS.</p><ul><li class="half_rhythm"><div>A decision about the timing and approach of an elective vascular procedure or the use of endovascular approaches is typically based on an individualized risk/benefit assessment.</div></li><li class="half_rhythm"><div>Reports of successful endovascular approaches are growing but no studies have compared outcomes with endovascular vs open repair.</div></li></ul><p>Prompt surgical intervention of bowel rupture is usually essential to limit the extent of infection and facilitate early restoration of bowel continuity.</p><ul><li class="half_rhythm"><div class="half_rhythm">Death from bowel rupture is uncommon because intervention is generally effective.</div></li><li class="half_rhythm"><div class="half_rhythm">Bowel continuity can be restored successfully in most instances, usually three to six months after the initial surgery.</div></li><li class="half_rhythm"><div class="half_rhythm">The recurrence of bowel tears proximal to the original site and the risk of complications resulting from repeat surgery have led some to recommend partial or total colectomy to reduce the risk of recurrent bowel rupture [<a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>].</div><div class="half_rhythm">Some physicians and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals consider total colectomy as a prophylactic measure to avoid recurrent bowel complications and the need for repeat surgery [<a class="bk_pop" href="#eds4.REF.fuchs.2004.e1">Fuchs &#x00026; Fishman 2004</a>].</div></li></ul></div><div id="eds4.Surveillance"><h3>Surveillance</h3><p>The use of surveillance of the arterial vasculature assumes that effective interventions will decrease the risk of arterial dissection or rupture and prolong life. At a time when an open surgical approach was the only option, the benefit of surveillance could not be established. As endovascular approaches to management of aneurysms and dissection become more available, earlier intervention is considered and surveillance is seen to have greater benefit. There are, however, no published data assessing the efficacy of screening strategies in identifying the regions in the arterial vasculature at highest risk; conversely, there are examples in which regions of concern in the arterial vasculature failed to progress and arterial rupture occurred at other more distant sites. Thus, the benefit of controlled studies cannot be overemphasized.</p><p>If undertaken, noninvasive imaging such as ultrasound examination, magnetic resonance angiogram, or computed tomography angiogram with and without venous contrast is preferred to identify aneurysms, dissections, and vascular ruptures [<a class="bk_pop" href="#eds4.REF.chu.2014.1120">Chu et al 2014</a>]. Because arterial tear/dissection may result at the site of entry of the catheter and at sites of high-pressure injection, conventional arteriograms are not recommended. When surveillance is undertaken, repeat measure depends on the pathology identified, but in the presence of a normal vascular tree, screening at 18-month intervals appears to be the usual practice.</p><p>Blood pressure monitoring on a regular basis is recommended to allow for early treatment if hypertension develops, thus reducing the risk for vascular stress and injury.</p></div><div id="eds4.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Trauma.</b> Because of inherent tissue fragility, it is prudent for individuals with vEDS to avoid collision sports (e.g., football), heavy lifting, and weight training with extreme lifting. Of note, no evidence suggests that moderate recreational exercise is detrimental.</p><p><b>Arteriography.</b> Conventional arterial angiography (with contrast injection) should be discouraged because it has been associated with added <i>de novo</i> complications [<a class="bk_pop" href="#eds4.REF.zilocchi.2007.712">Zilocchi et al 2007</a>]. Arterial tear/dissection may result at the site of entry of the catheter; furthermore, injection pressure may lead to arterial aneurysms. Arteriography is currently best used as part of a planned interventional procedure, such as coil embolization or stenting of bleeding arteries.</p><p><b>Routine colonoscopy.</b> There are several reports of colonoscopy-associated bowel perforation in individuals with vEDS. Virtual colonoscopy, which also involves insufflation, may have similar complications. Routine colonoscopy for cancer screening is discouraged in the absence of concerning symptoms or a strong family history of colorectal cancer. Individuals with vEDS who have a family history of colon cancer are encouraged to use genetic testing for colon cancer risk assessment (provided the genetic etiology of colon cancer has been established in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member). Use of capsular cameras may provide sufficient data in at-risk individuals.</p><p><b>Elective surgery.</b> Because tissue fragility results in a higher risk of surgical complications, elective surgery for individuals with vEDS is generally discouraged unless the benefit is expected to be substantial. In general, avoidance of surgery in favor of more conservative management is advised, although data about elective surgery are just beginning to emerge and this approach needs to be reevaluated.</p></div><div id="eds4.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual to identify as early as possible those who could benefit from surveillance, awareness of treatment for potential complications, and appropriate restriction of high-risk physical activities. Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known;</div></li><li class="half_rhythm"><div>Clinical evaluation if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known.</div></li></ul><p>See <a href="#eds4.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="eds4.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy has often been actively discouraged for women with vEDS because of high reported risks of mortality. The most extensive study, which included evaluation of more than 500 pregnancies in 253 women [<a class="bk_pop" href="#eds4.REF.murray.2014.874">Murray et al 2014</a>], found a mortality rate of about 5% per pregnancy. This is lower than previously identified and may be because a significant number of the women included knew about the diagnosis before pregnancy or delivery. The issue of management and recommendations is complicated by the recognition that many of the women who became pregnant, and their providers, learned of the diagnosis at the time of delivery and the onset of complications.</p><p>About half the women in the study had no complications. For others, prematurity, and uterine, cervical, and vaginal tears led to morbidity.</p><p>Increasingly, the practice is to plan delivery by cesarean section at 36-38 weeks to try to avoid the extensive tissue injury that can accompany vaginal delivery. This procedure can be associated with an increased risk of hemorrhage and inadvertent damage to nearby abdominal organs.</p><p>When the diagnosis is known in the mother, the maternal risks should be discussed and all options considered. The decision to proceed with pregnancy should involve enlarging the care team to include a high-risk obstetric service. Plans for early delivery should include the presence of the vascular surgeon and potentially the general surgeon.</p><p>It is essential to educate the pregnant woman regarding possible complications and the need for close monitoring.</p></div><div id="eds4.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A clinical trial in France to determine if addition of an angiotensin receptor blocker to celiprolol decreases arterial complications and extends life expectancy is currently underway.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="eds4.Genetic_Counseling"><h2 id="_eds4_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="eds4.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Vascular Ehlers-Danlos syndrome (vEDS) is almost always inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. There are rare reports of individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>COL3A1</i> [<a class="bk_pop" href="#eds4.REF.j_rgensen.2015.796">J&#x000f8;rgensen et al 2015</a>].</p></div><div id="eds4.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>About 50% of individuals diagnosed with vEDS have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with vEDS may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a <i>de novo</i> pathogenic variant is about 50%.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include physical examination and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in a parent.</div><ul><li class="half_rhythm"><div>The estimated rate of parental somatic and <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> is 2%-5%. To date, parents mosaic for a <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are not known to be symptomatic or to have had complications compatible with the diagnosis of vEDS, though further investigation is needed [<a class="bk_pop" href="#eds4.REF.legrand.2018">Legrand et al 2018</a>].</div></li><li class="half_rhythm"><div>Two families in which there appears to be isolated <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> have been identified [<a class="bk_pop" href="#eds4.REF.byers.2003.206">Byers et al 2003</a>, <a class="bk_pop" href="#eds4.REF.palmeri.2003.510">Palmeri et al 2003</a>].</div></li></ul></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with vEDS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disorder in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs depends on the clinical/genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or is known to have the <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to each sib is 50%.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a known <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to the sibs is about 1% because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are still presumed to be at increased risk for vEDS because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent or parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with vEDS has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and developing complications of the disorder.</div></li><li class="half_rhythm"><div>In the rare occurrence in which an individual has <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>COL3A1</i> pathogenic variants, 100% of offspring will inherit one of the variants and may be symptomatic.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="eds4.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#eds4.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, additional explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>Testing of asymptomatic individuals younger than age 18 years.</b> The benefits of testing individuals younger than age 18 years for vEDS include: (1) elimination of concern for those children who do not have the <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; (2) awareness of and preparedness for potential complications; and (3) restriction of high-impact sports and high-risk activities for those with the pathogenic variant.</p><p>Although vEDS is often considered an adult-onset condition, 12%-24% of individuals have a major complication by age 20 years [<a class="bk_pop" href="#eds4.REF.pepin.2014.881">Pepin et al 2014</a>, <a class="bk_pop" href="#eds4.REF.frank.2015.1657">Frank et al 2015</a>]. Genetic testing of at-risk children has been controversial because of the concern that there is no preventive treatment. However, awareness of the condition is a key component of appropriate intervention in the occurrence of a major complication and for implementation of risk-reducing behaviors. In this context, 87% of children tested before age 18 years had not experienced a major complication and the mean age of testing was eight years. Given the opportunity to consider testing for children at 50% risk of having inherited the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, parents usually did not wait until a complication arose or until the child reached majority for a test to be performed. Instead, they requested that the test be performed to clarify the child's status and allow them to anticipate medical risks [Author, personal communication].</p><p>In a family with an established diagnosis of vEDS it is appropriate to consider testing symptomatic individuals regardless of age.</p><p>For more information, see the National Society of Genetic Counselors <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">position statement</a> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">policy statement</a>: ethical and policy issues in genetic testing and screening of children.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="eds4.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for vEDS are possible. Given the efficiency of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> and the recognition that essentially all individuals with a biochemical diagnosis of vEDS also have a known <i>COL3A1</i> pathogenic variant, molecular genetic testing is the recommended approach for prenatal testing. Experience with use of assisted reproductive technologies for women with vEDS is limited [<a class="bk_pop" href="#eds4.REF.bergeron.2014.141">Bergeron et al 2014</a>].</p><p><b>Biochemical testing.</b> In rare families in which only the biochemical abnormality of type III collagen is known, analysis of cultured CVS cells can be used as an alternative to molecular genetic prenatal testing. Biochemical testing for <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> of vEDS should be performed only if the molecular etiology cannot be identified.</p></div></div><div id="eds4.Resources"><h2 id="_eds4_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Annabelle's Challenge</b></div><div>Europa House</div><div>Barcroft Street</div><div> Bury BL9 5BT</div><div>United Kingdom</div><div><b>Phone:</b> 0161 763 8741; 0800 917 8495</div><div><a href="https://www.annabelleschallenge.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.annabelleschallenge.org</a></div></li><li class="half_rhythm"><div><b>Association Francaise des Syndrome d'Ehlers Danlos (AFSED)</b></div><div>67, rue Jules Lecesne</div><div>Le Havre 76600</div><div>France</div><div><b>Phone:</b> 0820 20 37 33</div><div><b>Email:</b> contact@afsed.com</div><div><a href="http://afsed.fr/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.afsed.fr</a></div></li><li class="half_rhythm"><div><b>DEFY Foundation</b></div><div>P.O. Box 3386</div><div>West Chester PA 19381</div><div><b>Email:</b> info@defy-foundation.org</div><div><a href="http://www.defy-foundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.defy-foundation.org/</a></div></li><li class="half_rhythm"><div><b>Ehlers-Danlos Society - Europe</b></div><div>35-37 Ludgate Hill</div><div>Office 7</div><div>London EC4M 7JN</div><div>United Kingdom</div><div><b>Phone:</b> +44 203 887 6132</div></li><li class="half_rhythm"><div><b>Ehlers-Danlos Society Headquarters</b></div><div>P.O. Box 87463</div><div>Montgomery Village MD 20886</div><div><b>Phone:</b> 410-670-7577</div><div><b>Email:</b> info@ehlers-danlos.com</div><div><a href="https://ehlers-danlos.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ehlers-danlos.com</a></div></li><li class="half_rhythm"><div><b>Ehlers-Danlos Support Group</b></div><div>PO Box 337</div><div>Aldershot Surrey GU12 6WZ</div><div>United Kingdom</div><div><b>Phone:</b> 01252 690940</div><div><b>Email:</b> director@ehlers-danlos.org</div><div><a href="http://www.ehlers-danlos.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ehlers-danlos.org</a></div></li><li class="half_rhythm"><div><b>Ehlers-Danlos Support UK</b></div><div>PO Box 748</div><div>Borehamwood WD6 9HU</div><div>United Kingdom</div><div><b>Phone:</b> 0208 736 5604; 0800 9078518</div><div><a href="https://www.ehlers-danlos.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ehlers-danlos.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Ehlers-Danlos%20syndrome%20-%20Vascular%20type&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ehlers-Danlos syndrome - Vascular type</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=ehlersdanlossyndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ehlers-Danlos syndrome</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ehlersdanlossyndrome.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ehlers-Danlos Syndrome</a></div></li><li class="half_rhythm"><div><b>Ehlers-Danlos Society EDS &#x00026; Related Disorders Global Registry</b></div><div><a href="https://www.ehlers-danlos.com/eds-global-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ehlers-danlos.com/eds-global-registry</a></div></li></ul></div><div id="eds4.Molecular_Genetics"><h2 id="_eds4_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="eds4.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Vascular Ehlers-Danlos Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1494/table/eds4.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__eds4.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_eds4.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_eds4.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_eds4.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_eds4.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_eds4.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_eds4.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_eds4.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1281" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>COL3A1</i></a></td><td headers="hd_b_eds4.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1281" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q32<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_eds4.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P02461" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen alpha-1(III) chain</a></td><td headers="hd_b_eds4.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://eds.gene.le.ac.uk/home.php?select_db=COL3A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Ehlers-Danlos Syndrome Variant Database COL3A1</a><br /><a href="http://www.le.ac.uk/genetics/collagen/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Database of osteogenesis imperfecta and type III collagen mutations</a></td><td headers="hd_b_eds4.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=COL3A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL3A1</a></td><td headers="hd_b_eds4.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=COL3A1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COL3A1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="eds4.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="eds4.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Vascular Ehlers-Danlos Syndrome (<a href="/omim/120180,130050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1494/table/eds4.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__eds4.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/120180" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">120180</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COLLAGEN, TYPE III, ALPHA-1; COL3A1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/130050" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">130050</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">EHLERS-DANLOS SYNDROME, VASCULAR TYPE; EDSVASC</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>COL3A1</i> comprises 51 exons distributed over 44 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA (reference sequence <a href="/nuccore/NM_000090.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000090.3</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1494/#eds4.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Note on <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein nomenclature.</b> For fibrillar collagen genes of the same clade (<i>COL1A1</i>, <i>COL1A2</i>, <i>COL2A1</i>, <i>COL3A1</i>, and <i>COL5A2</i>) there is a "legacy" naming system so that all genes have 52 exons &#x02013; derived from the structure of <i>COL1A2</i>. In the case of <i>COL3A1</i>, there is fusion of two exons that are equivalent to exons 4 and 5 in <i>COL1A2</i> and the fusion <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> is called exon 4/5. In addition, there is a second "legacy" protein naming system in which, in addition to the use of the p.Met1 nomenclature, there is a system in which the first glycine of the canonic triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> is referred to as residue 1 in the triple helix. In reports from some laboratories, both systems are used and the difference in protein position between the two systems is indicated. In older reports from some laboratories, the legacy description for protein may be used in combination with the standard description for nucleotide position, leading to considerable confusion.</p><p><b>Pathogenic variants.</b> More than 600 <i>COL3A1</i> variants that result in a disease-causing <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been identified.</p><p>The majority of identified pathogenic variants result in single-amino acid substitutions for glycines in the Gly-X-Y repeat of the triple helical region of the type III procollagen molecule. About a quarter of reported pathogenic variants occur at splice sites, most resulting in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping. A smaller number of <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants lead to the use of cryptic splice sites with partial-exon exclusion or <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> inclusion. The vast majority of exon-skipping splice site variants have been identified at the 5' donor site, with very few found at the 3' splice site.</p><p>Several partial-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions have been reported as well. Less common are variants that create premature termination codons predicted to result in <i>COL3A1</i> <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> ("<a class="def" href="/books/n/gene/glossary/def-item/null/">null</a>" pathogenic variants) [<a class="bk_pop" href="#eds4.REF.schwarze.2001.989">Schwarze et al 2001</a>, <a class="bk_pop" href="#eds4.REF.leistritz.2011.717">Leistritz et al 2011</a>]. (See <a href="http://www.le.ac.uk/genetics/collagen" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Database of Human Type I and Type III Collagen Mutations</a>.)</p><p>Of note, at least two classes of <i>COL3A1</i> variants are underrepresented (in terms of predicted frequency) among individuals with clinical features of vEDS:</p><ul><li class="half_rhythm"><div>Substitutions of glycine in the triple helical <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> by alanine</div></li><li class="half_rhythm"><div>Null variants</div></li></ul><p>Thus, some pathogenic variants in <i>COL3A1</i> may not produce a typical vEDS clinical picture. It is unclear if individuals with these classes of pathogenic variants have attenuated or subclinical phenotypes and present at later ages or if there is a molecular explanation for the absence of certain <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> types.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>COL3A1</i> encodes the pro&#x003b1;1(III) chain of type III procollagen, a major structural component of skin, blood vessels, and hollow organs. The type III procollagen molecule is a homotrimer, with constituent chains 1,466 amino acids in length.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>COL3A1</i> typically result in a structural alteration of type III collagen that leads to intracellular storage and impaired secretion of collagen chains. Production of half the normal amount of type III procollagen occurs in a minority of individuals.</p></div><div id="eds4.References"><h2 id="_eds4_References_">References</h2><div id="eds4.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="eds4.REF1">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <a href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2013. Accessed 5-21-19. [<a href="/pubmed/23428972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23428972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF2">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <a href="http://www.nsgc.org/p/bl/et/blogaid=860" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2018. Accessed 5-21-19.</div></li></ul></div><div id="eds4.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.adham.2018.100">Adham S, Trystram D, Albuisson J, Domigo V, Legrand A, Jeunemaitre X, Frank M. Pathophysiology of carotid-cavernous fistulas in vascular Ehlers-Danlos syndrome: a retrospective cohort and comprehensive review. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2018;<span class="ref-vol">13</span>:100.</span> [<a href="/pmc/articles/PMC6019721/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6019721</span></a>] [<a href="/pubmed/29940997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29940997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.ahmadi.2011.226">Ahmadi J, Choi JN. Newly diagnosed Ehlers-Danlos syndrome in an adult with elastosis perforans serpiginosa. <span><span class="ref-journal">J Am Acad Dermatol. </span>2011;<span class="ref-vol">65</span>:226–7.</span> [<a href="/pubmed/21679829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21679829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.barabas.1967.612">Barabas AP. Heterogeneity of the Ehlers-Danlos syndrome: description of three clinical types and a hypothesis to explain the basic defect(s). <span><span class="ref-journal">Br Med J. </span>1967;<span class="ref-vol">2</span>:612–3.</span> [<a href="/pmc/articles/PMC1842124/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1842124</span></a>] [<a href="/pubmed/6025600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6025600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.bergeron.2014.141">Bergeron ME, Child T, Fatum M. In vitro maturation and surrogacy in patients with vascular-type Ehlers-Danlos syndrome--a safe assisted reproductive technology approach. <span><span class="ref-journal">Hum Fertil (Camb). </span>2014;<span class="ref-vol">17</span>:141–4.</span> [<a href="/pubmed/24758138" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24758138</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.byers.2003.206">Byers PH, Pepin MG, Schwarze U, Gaulke LK. Recurrence risk and asymptomatic and symptomatic mosaicism in Ehlers-Danlos syndrome (EDS) type IV. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">73S</span>:206.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.chu.2014.1120">Chu LC, Johnson PT, Dietz HC, Fishman EK. CT angiographic evaluation of genetic vascular disease: role in detection, staging, and management of complex vascular pathologic conditions. <span><span class="ref-journal">AJR Am J Roentgenol. </span>2014;<span class="ref-vol">202</span>:1120–9.</span> [<a href="/pubmed/24758669" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24758669</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.ferr_.2012.e000705">Ferr&#x000e9; FC, Frank M, Gogly B, Golmard L, Naveau A, Ch&#x000e9;rifi H, Emmerich J, Gaultier F, Berdal A, Jeunemaitre X, Fournier BP. Oral phenotype and scoring of vascular Ehlers-Danlos syndrome: a case-control study. <span><span class="ref-journal">BMJ Open. </span>2012;<span class="ref-vol">2</span>:e000705.</span> [<a href="/pmc/articles/PMC3323826/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3323826</span></a>] [<a href="/pubmed/22492385" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22492385</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.frank.2015.1657">Frank M, Albuisson J, Ranque B, Golmard L, Mazzella JM, Bal-Theoleyre L, Fauret AL, Mirault T, Denari&#x000e9; N, Mousseaux E, Boutouyrie P, Fiessinger JN, Emmerich J, Messas E, Jeunemaitre X. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. <span><span class="ref-journal">Eur J Hum Genet. </span>2015;<span class="ref-vol">23</span>:1657–64.</span> [<a href="/pmc/articles/PMC4795191/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4795191</span></a>] [<a href="/pubmed/25758994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25758994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.fuchs.2004.e1">Fuchs JR, Fishman SJ. Management of spontaneous colonic perforation in Ehlers-Danlos syndrome type IV. <span><span class="ref-journal">J Pediatr Surg. </span>2004;<span class="ref-vol">39</span>:e1–3.</span> [<a href="/pubmed/14966763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14966763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.garc_a_s_ez.2014.1804">Garc&#x000ed;a S&#x000e1;ez D, Mohite PN, Zych B, Sabashnikov A, Moza A, Carby M, Simon AR. Bilateral lung transplantation in a patient with vascular Ehlers-Danlos syndrome. <span><span class="ref-journal">Ann Thorac Surg. </span>2014;<span class="ref-vol">97</span>:1804–6.</span> [<a href="/pubmed/24792277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24792277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.hatake.2013.23">Hatake K, Morimura Y, Kudo R, Kawashima W, Kasuda S, Kuniyasu H. Respiratory complications of Ehlers-Danlos syndrome type IV. <span><span class="ref-journal">Leg Med (Tokyo). </span>2013;<span class="ref-vol">15</span>:23–7.</span> [<a href="/pubmed/22940417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22940417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.j_rgensen.2015.796">J&#x000f8;rgensen A, Fagerheim T, Rand-Hendriksen S, Lunde PI, Vorren TO, Pepin MG, Leistritz DF, Byers PH. Vascular Ehlers-Danlos syndrome in siblings with biallelic COL3A1 sequence variants and marked clinical variability in the extended family. <span><span class="ref-journal">Eur J Hum Genet. </span>2015;<span class="ref-vol">23</span>:796–802.</span> [<a href="/pmc/articles/PMC4795069/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4795069</span></a>] [<a href="/pubmed/25205403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25205403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.kawabata.2010.944">Kawabata Y, Watanabe A, Yamaguchi S, Aoshima M, Shiraki A, Hatamochi A, Kawamura T, Uchiyama T, Watanabe A, Fukuda Y. Pleuropulmonary pathology of vascular Ehlers-Danlos syndrome: spontaneous laceration, haematoma and fibrous nodules. <span><span class="ref-journal">Histopathology. </span>2010;<span class="ref-vol">56</span>:944–50.</span> [<a href="/pubmed/20500229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20500229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.kuming.1977.403">Kuming BS, Joffe L. Ehlers-Danlos syndrome associated with keratoconus. A case report. <span><span class="ref-journal">S Afr Med J. </span>1977;<span class="ref-vol">52</span>:403–5.</span> [<a href="/pubmed/897848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 897848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.legrand.2018">Legrand A, Devriese M, Dupuis-Girod S, Simian C, Venisse A, Mazzella JM, Auribault K, Adham S, Frank M, Albuisson J, Jeunemaitre X. Frequency of de novo variants and parental mosaicism in vascular Ehlers-Danlos syndrome. <span><span class="ref-journal">Genet Med. </span>2018.</span> Epub ahead of print. [<a href="/pubmed/30474650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30474650</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.leistritz.2011.717">Leistritz DF, Pepin MG, Schwarze U, Byers PH. COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. <span><span class="ref-journal">Genet Med. </span>2011;<span class="ref-vol">13</span>:717–22.</span> [<a href="/pubmed/21637106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21637106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.malfait.2017.8">Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, Bloom L, Bowen JM, Brady AF, Burrows NP, Castori M, Cohen H, Colombi M, Demirdas S, De Backer J, De Paepe A, Fournel-Gigleux S, Frank M, Ghali N, Giunta C, Grahame R, Hakim A, Jeunemaitre X, Johnson D, Juul-Kristensen B, Kapferer-Seebacher I, Kazkaz H, Kosho T, Lavallee ME, Levy H, Mendoza-Londono R, Pepin M, Pope FM, Reinstein E, Robert L, Rohrbach M, Sanders L, Sobey GJ, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Wheeldon N, Zschocke J, Tinkle B. The 2017 international classification of the Ehlers-Danlos syndromes. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2017;<span class="ref-vol">175</span>:8–26.</span> [<a href="/pubmed/28306229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28306229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.malfait.2007.387">Malfait F, Symoens S, De Backer J, Hermanns-L&#x000ea; T, Sakalihasan N, Lapi&#x000e8;re CM, Coucke P, De Paepe A. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:387–95.</span> [<a href="/pubmed/17211858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17211858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.malfait.2005.28">Malfait F, Coucke P, Symoens S, Loeys B, Nuytinck L, De Paepe A. The molecular basis of classic Ehlers-Danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:28–37.</span> [<a href="/pubmed/15580559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15580559</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.meienberg.2010.1315">Meienberg J, Rohrbach M, Neuenschwander S, Spanaus K, Giunta C, Alonso S, Arnold E, Henggeler C, Regenass S, Patrignani A, Azzarello-Burri S, Steiner B, Nygren AO, Carrel T, Steinmann B, M&#x000e1;ty&#x000e1;s G. Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency. <span><span class="ref-journal">Eur J Hum Genet. </span>2010;<span class="ref-vol">18</span>:1315–21.</span> [<a href="/pmc/articles/PMC3002852/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3002852</span></a>] [<a href="/pubmed/20648054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.murray.2014.874">Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complications in women with vascular Ehlers-Danlos syndrome. <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:874–80.</span> [<a href="/pubmed/24922461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24922461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.narcisi.1994.1617">Narcisi P, Richards AJ, Ferguson SD, Pope FM. A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. <span><span class="ref-journal">Hum Mol Genet. </span>1994;<span class="ref-vol">3</span>:1617–20.</span> [<a href="/pubmed/7833919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7833919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.nuytinck.2000.1398">Nuytinck L, Freund M, Lagae L, Pierard GE, Hermanns-Le T, De Paepe A. Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">66</span>:1398–402.</span> [<a href="/pmc/articles/PMC1288203/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288203</span></a>] [<a href="/pubmed/10739762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10739762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.ng.2005.320">Ng SC, Muiesan P. Spontaneous liver rupture in Ehlers-Danlos syndrome type IV. <span><span class="ref-journal">J R Soc Med. </span>2005;<span class="ref-vol">98</span>:320–2.</span> [<a href="/pmc/articles/PMC1168920/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1168920</span></a>] [<a href="/pubmed/15994597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15994597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.oderich.2005.98">Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, Kalra M, Sullivan T, Gloviczki P. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. <span><span class="ref-journal">J Vasc Surg. </span>2005;<span class="ref-vol">42</span>:98–106.</span> [<a href="/pubmed/16012458" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16012458</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.palmeri.2003.510">Palmeri S, Mari F, Meloni I, Malandrini A, Ariani F, Villanova M, Pompilio A, Schwarze U, Byers PH, Renieri A. Neurological presentation of Ehlers-Danlos syndrome type IV in a family with parental mosaicism. <span><span class="ref-journal">Clin Genet. </span>2003;<span class="ref-vol">63</span>:510–5.</span> [<a href="/pubmed/12786757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12786757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.pepin.2000.673">Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. <span><span class="ref-journal">N Engl J Med. </span>2000;<span class="ref-vol">342</span>:673–80.</span> [<a href="/pubmed/10706896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10706896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.pepin.2014.881">Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). <span><span class="ref-journal">Genet Med. </span>2014;<span class="ref-vol">16</span>:881–8.</span> [<a href="/pubmed/24922459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24922459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.pope.1996.163">Pope FM, Narcisi P, Nicholls AC, Germaine D, Pals G, Richards AJ. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. <span><span class="ref-journal">Br J Dermatol. </span>1996;<span class="ref-vol">135</span>:163–81.</span> [<a href="/pubmed/8881656" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8881656</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.rana.2011.229">Rana M, Aziz O, Purkayastha S, Lloyd J, Wolfe J, Ziprin P. Colonoscopic perforation leading to a diagnosis of Ehlers Danlos syndrome type IV: a case report and review of the literature. <span><span class="ref-journal">J Med Case Rep. </span>2011;<span class="ref-vol">5</span>:229.</span> [<a href="/pmc/articles/PMC3141693/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3141693</span></a>] [<a href="/pubmed/21699676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21699676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.schwarze.2001.989">Schwarze U, Schievink WI, Petty E, Jaff MR, Babovic-Vuksanovic D, Cherry KJ, Pepin M, Byers PH. Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:989–1001.</span> [<a href="/pmc/articles/PMC1274375/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274375</span></a>] [<a href="/pubmed/11577371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11577371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.shalhub.2014.160">Shalhub S, Black JH 3rd, Cecchi AC, Xu Z. Griswold BF4, Safi HJ5, Milewicz DM3, McDonnell NB4. Molecular diagnosis in vascular Ehlers-Danlos syndrome predicts pattern of arterial involvement and outcomes. <span><span class="ref-journal">J Vasc Surg. </span>2014;<span class="ref-vol">60</span>:160–9.</span> [<a href="/pmc/articles/PMC4396069/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4396069</span></a>] [<a href="/pubmed/24650746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24650746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.van_de_luijtgaarden.2015.881">van de Luijtgaarden KM, Heijsman D, Maugeri A, Weiss MM, Verhagen HJ, IJpma A, Br&#x000fc;ggenwirth HT, Majoor-Krakauer D. First genetic analysis of aneurysm genes in familial and sporadic abdominal aortic aneurysm. <span><span class="ref-journal">Hum Genet. </span>2015;<span class="ref-vol">134</span>:881–93.</span> [<a href="/pmc/articles/PMC4495250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4495250</span></a>] [<a href="/pubmed/26017485" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26017485</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="eds4.REF.zilocchi.2007.712">Zilocchi M, Macedo TA, Oderich GS, Vrtiska TJ, Biondetti PR, Stanson AW. Vascular Ehlers-Danlos syndrome: imaging findings. <span><span class="ref-journal">AJR Am J Roentgenol. </span>2007;<span class="ref-vol">189</span>:712–9.</span> [<a href="/pubmed/17715121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17715121</span></a>]</div></li></ul></div></div><div id="eds4.Chapter_Notes"><h2 id="_eds4_Chapter_Notes_">Chapter Notes</h2><div id="eds4.Author_Notes"><h3>Author Notes</h3><p><a href="http://www.pathology.washington.edu/clinical/collagen/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Collagen Diagnostic Laboratory website</a></p></div><div id="eds4.Author_History"><h3>Author History</h3><p>Peter H Byers, MD (1999-present)<br />Mitzi L Murray, MD, MA; University of Washington (2015-2019)<br />Melanie G Pepin, MS, CGC; University of Washington (1999-2019)</p></div><div id="eds4.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 February 2019 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 November 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 May 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 June 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 January 2005 (cd) Revision: change in availability of clinical testing</div></li><li class="half_rhythm"><div>14 April 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 April 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 September 1999 (me) Review posted live</div></li><li class="half_rhythm"><div>6 April 1999 (mp) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1494</span><span class="label">PMID: <a href="/pubmed/20301667" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301667</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/porphyria-var/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/vlcad/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1494&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1494/?report=reader">PubReader</a></li><li><a href="/books/NBK1494/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1494" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1494" style="display:none" title="Cite this Page"><div class="bk_tt">Byers PH. Vascular Ehlers-Danlos Syndrome. 1999 Sep 2 [Updated 2019 Feb 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1494/pdf/Bookshelf_NBK1494.pdf">PDF version of this page</a> (478K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#eds4.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#eds4.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#eds4.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#eds4.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#eds4.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#eds4.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#eds4.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#eds4.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#eds4.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#eds4.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#eds4.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1281[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">COL3A1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1477934" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1477934" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1477934" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1477934" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301312" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Loeys-Dietz Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Loeys-Dietz Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Loeys BL, Dietz HC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301422" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Classic Ehlers-Danlos Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Classic Ehlers-Danlos Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Malfait F, Wenstrup R, De Paepe A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31353273" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis.</a><span class="source">[J Vasc Surg. 2020]</span><div class="brieflinkpop offscreen_noflow">A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shalhub S, Byers PH, Hicks KL, Coleman DM, Davis FM, De Caridi G, Weaver KN, Miller EM, Schermerhorn ML, Shean K, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Vasc Surg. 2020 Jan; 71(1):149-157. Epub 2019 Jul 26.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301510" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Marfan Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dietz H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25526469" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Vascular Ehlers-Danlos syndrome without the characteristic facial features: a case report.</a><span class="source">[Medicine (Baltimore). 2014]</span><div class="brieflinkpop offscreen_noflow">Vascular Ehlers-Danlos syndrome without the characteristic facial features: a case report.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Inokuchi R, Kurata H, Endo K, Kitsuta Y, Nakajima S, Hatamochi A, Yahagi N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Medicine (Baltimore). 2014 Dec; 93(28):e291. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301667" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301667" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04118fdd21425a25a52abe">Vascular Ehlers-Danlos Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Vascular Ehlers-Danlos Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:49:03-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AD7C5E040D4E10000000001D500B1&amp;ncbi_session=CE8AD7C5E04118F1_0469SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1494%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1494&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1494/&amp;ncbi_pagename=Vascular Ehlers-Danlos Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AD7C5E04118F1_0469SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>